The present disclosure relates to compositions and methods for using cells having cellular immunotherapies comprising a composition of chimeric antigen receptor (CAR)-modified CD4+ T cells and a composition of CD8+ T cells modified with a distinct CAR in that the intracellular signaling component of the each CAR is different, wherein the modified CD4+ and CD8+ T cells have enhanced helper and effector functions, respectively, and together more effectively augment the immune response. Such cellular immunotherapies are useful in treating disease, such as cancer.
